ICU Medical (ICUI) Q4 2010 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2010 earnings summary
6 Nov, 2026Executive summary
Revenue rose to $284.6M in 2010 from $231.5M in 2009; growth reflected higher sales across product lines and expanded direct critical-care sales after the Hospira asset purchase.
Strategy centered on custom products, new product development, broader distribution, and international expansion; Hospira remained the largest customer at 44% of 2010 revenue.
Financial highlights
Revenue was $284.6M, gross profit $130.6M, operating income $49.3M, and net income $30.9M in 2010; 2009 comparatives were $231.5M, $108.8M, $38.0M, and $26.6M.
Diluted EPS was $2.23 in 2010 versus $1.77 in 2009; operating income represented 17% of revenue and net income 11%.
Gross margin was 46%, down from 47% in 2009; critical-care integration and higher freight costs were partly offset by favorable product mix.
SG&A was $76.6M, or 27% of revenue, versus $68.2M, or 30%; R&D was $4.7M, or 2%, versus $2.6M, or 1%.
Operating cash flow was $33.1M versus $51.1M; year-end cash, cash equivalents and investments totaled $93.4M, down from $108.1M.
Outlook and guidance
Expected 2011 growth versus 2010 was modest for CLAVE, custom products, critical care, and international sales; domestic distributor/direct sales were expected to rise, principally from CLAVE, oncology, and renal products.
2011 SG&A guidance was 27.0%-27.5% of revenue; R&D was expected at ~2% of revenue and the effective tax rate at ~36%.
Estimated 2011 capital expenditures were $16M-$19M, mainly for molds, machinery, equipment, and information technology.
Existing cash, investments, and expected operating cash generation were considered sufficient to fund operations for the next 12 months.
Latest events from ICU Medical
- Record revenue and cash flow, led by infusion and oncology, offset critical care pressure.ICUI
Q4 2011 - Record FY09 revenue and earnings accompanied a major shift to direct critical care sales.ICUI
Q4 2009 - Record revenue and stronger margins, offset by lower earnings and critical care sales.ICUI
Q4 2012 - Normalized IV Solutions demand cut FY19 revenue, while cash and integration savings supported resilience.ICUI
Q4 2019 - Record FY16 growth funded an infusion transformation, with integration the near-term test.ICUI
Q4 2016 - Record FY15 performance, with growth led by Infusion and Oncology and diversification still critical.ICUI
Q4 2015 - HIS expanded the portfolio, but integration costs drove a FY2017 operating loss.ICUI
Q4 2017 - Integration neared completion as cash grew, but reported earnings absorbed heavy one-time charges.ICUI
Q4 2018 - Infusion Systems growth and record operating cash flow cushioned pandemic-driven weakness elsewhere.ICUI
Q4 2020